LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

433.1 -0.04

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

432.05

Massimo

438.16

Metriche Chiave
By Trading Economics
Entrata	-160M 1B
Vendite	-240M 3B
P/E Media del settore	25.91 49.701
EPS	4.47
Margine di Profitto	34.531
Dipendenti	6,400
EBITDA	-215M 1.1B

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+29.84% upside

Dividendi
By Dow Jones
Utili prossimi	3 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2.4B 111B
Apertura precedente	433.14
Chiusura precedente	433.1

Notizie sul Sentiment di mercato

By Acuity

40%

60%

114 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

428.545 / 498.65 Supporto e resistenza

Vertex Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 mag 2026, 20:57 UTC

Utili

Vertex Pharmaceuticals Posts Higher 1Q Profit

12 feb 2026, 21:47 UTC

Utili

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

3 nov 2025, 21:44 UTC

Utili

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

5 ago 2025, 00:05 UTC

Azioni calde

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4 ago 2025, 21:21 UTC

Utili

I principali Market Mover

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 ago 2025, 20:45 UTC

Utili

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 mag 2026, 20:02 UTC

Utili

Vertex Pharmaceuticals Reiterates 2026 Guidance

4 mag 2026, 20:01 UTC

Utili

Vertex Pharmaceuticals 1Q Net $1.03B >VRTX

4 mag 2026, 20:01 UTC

Utili

Vertex Pharmaceuticals 1Q Rev $2.99B >VRTX

4 mag 2026, 20:01 UTC

Utili

Vertex Pharmaceuticals 1Q Adj EPS $4.47 >VRTX

4 mag 2026, 20:01 UTC

Utili

Vertex Pharmaceuticals 1Q EPS $4.02 >VRTX

12 feb 2026, 21:13 UTC

Utili

Vertex Pharmaceuticals Guidance Includes Immaterial Cost Impact From Tariffs in 2026 >VRTX

12 feb 2026, 21:13 UTC

Utili

Vertex Pharmaceuticals Sees FY26 Rev $12.95B-$13.1B >VRTX

12 feb 2026, 21:01 UTC

Utili

Vertex Pharmaceuticals 4Q Rev $3.19B >VRTX

12 feb 2026, 21:01 UTC

Utili

Vertex Pharmaceuticals 4Q Net $1.19B >VRTX

12 feb 2026, 21:01 UTC

Utili

Vertex Pharmaceuticals 4Q EPS $4.65 >VRTX

12 feb 2026, 21:01 UTC

Utili

Vertex Pharmaceuticals 4Q Adj EPS $5.03 >VRTX

3 nov 2025, 21:05 UTC

Utili

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov 2025, 21:02 UTC

Utili

Vertex Pharmaceuticals 3Q EPS $4.20 >VRTX

3 nov 2025, 21:02 UTC

Utili

Vertex Pharmaceuticals 3Q Adj EPS $4.80 >VRTX

3 nov 2025, 21:02 UTC

Utili

Vertex Pharmaceuticals 3Q Net $1.08B >VRTX

3 nov 2025, 21:02 UTC

Utili

Vertex Pharmaceuticals 3Q Rev $3.08B >VRTX

5 ago 2025, 20:44 UTC

Utili

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 ago 2025, 18:17 UTC

Utili

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 ago 2025, 15:25 UTC

Utili

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 ago 2025, 14:12 UTC

Utili

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5 ago 2025, 11:27 UTC

Utili

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 ago 2025, 10:55 UTC

Utili

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 ago 2025, 10:36 UTC

Utili

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 ago 2025, 10:18 UTC

Utili

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Vertex Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

29.84% in crescita

Previsioni per 12 mesi

Media 562.9 USD 29.84%

Alto 641 USD

Basso 436 USD

Basato su 24 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Vertex Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

24 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 24 che hanno fornito valutazioni azionarie a Vertex Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

428.545 / 498.65Supporto e resistenza

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

114 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.